Opportunities Preloader

Please Wait.....

Report

Glaucoma - Epidemiology Forecast - 2032

Market Report (24 hrs) I 2022-05-01 I 139 Pages I DelveInsight

DelveInsights GlaucomaEpidemiology Forecast2032 report delivers an in-depth understanding of the Glaucoma , historical and forecasted epidemiology as well as the Glaucoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Glaucoma Disease Understanding
According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The angle in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.
Open-angle glaucoma (OAG) is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This causes pressure in the eye to increase gradually and damages the optic nerve. It happens so slowly that the patient may lose vision before they are even aware of a problem, while in the case of narrow-angle glaucoma, the structure inside the eye that allows fluid to drain normally from the eye (called the drainage angle) becomes restricted. Narrow drainage angles in the eye increase the risk of the drainage angle that gets blocked, resulting in a significant increase in eye pressure and risk of vision loss. If this occurs, narrow-angle glaucoma is usually called angle-closure glaucoma.
Continued in the report..
Glaucoma Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma, Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Glaucoma Detailed Epidemiology Segmentation
The total diagnosed prevalent population of Glaucoma in the 7MM was 11,048,000 in 2021, which is expected to increase in the forecast period (2022-2032).
Among the five European countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,115,113 cases, followed by Italy and France in 2021. On the other hand, Spain had the lowest.
Japan had 3,387,932 diagnosed prevalent cases for Glaucoma in 2021.
In 2021, in the United States, open-angle glaucoma was more prominent than closed angle with total cases of 3,119,031 cases of open angle glaucoma. Out of these total open-angle glaucoma cases, 2,807,128 cases were of primary open-angle glaucoma whereas secondary open-angle glaucoma had 311,903 cases in the United States in 2021.
There were a total of 273,002 cases of steroid induced glaucoma in Japan in 2021. These cases are anticipated to decrease during the forecast period.
Highest number of cases of glaucoma in the 7MM wre observed in the 40years and above age group with a total of 10,099,987cases in 2021. The least number of cases were observed in 2 to <18 years of age group. These cases are anticipated to increase during the forecast period.
As per DelveInsights analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries. The highest proportion of Gluacoma cases was observed in 40 years and above age group in the 7MM. Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases.
Scope of the Report
The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Glaucoma.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma.

Report Highlights
11-Year Forecast of Glaucoma
7MM Coverage
Total Diagnosed Prevalence of Glaucoma
Type-specific Diagnosed Prevalence of Glaucoma
Type-specific Diagnosed Prevalence of Open-Angle Glaucoma
Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma
Gender-specific Diagnosed Prevalence of Glaucoma
Age-specific Diagnosed Prevalence of Glaucoma
Key Questions Answered
What are the disease risk, and burden of Glaucoma ?
What is the historical Glaucoma patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
What would be the forecasted patient pool of Glaucoma at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glaucoma ?
Out of the above-mentioned countries, which country would have the highest prevalent population of Glaucoma during the forecast period (20222032)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (20222032)?
Reasons to buy
The Glaucoma report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the 7MM Glaucoma epidemiology forecast.
The Glaucoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The Glaucoma epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
The United States
EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 20192032

1. Key Insights
2. Report Introduction
3. Executive Summary of Glaucoma
4. Disease Background and Overview
4.1. Introduction
4.2. Classification of Glaucoma
4.2.1. Classification of Open-Angle Glaucoma (OAG)
4.2.1.1. Primary Open-Angle Glaucoma (POAG)
4.2.1.2. Secondary Open-Angle Glaucoma
4.2.2. Classification of Close-Angle Glaucoma/Angle-closure glaucoma (ACG)
4.3. Signs and Symptoms of Glaucoma
4.3.1. Signs and Symptoms of Open-Angle Glaucoma
4.3.2. Signs and Symptoms of Closed-angle Glaucoma
4.4. Genes Involved in Glaucoma
4.4.1. Primary Open Angle Glaucoma
4.4.2. Primary Closed Angle Glaucoma (PACG)
4.5. Diagnosis
4.5.1. Diagnosis of Glaucoma
4.5.2. Diagnostic criteria of Angle Closure Glaucoma
4.5.3. Differential Diagnosis of Glaucoma
4.5.4. Diagnostic Algorithm for Glaucoma
4.5.5. Diagnosis of Juvenile Open Angle Glaucoma (JOAG)
4.5.6. Diagnosis of Steroid Induced Glaucoma (SIG)
4.5.7. Primary Glaucoma Preferred Practice Pattern guidelines
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidemiology Methodology
5.3. Total Diagnosed Prevalence of Glaucoma in the 7MM
5.4. Assumptions and Rationales: 7MM
5.5. The United States
5.5.1. Total Diagnosed Prevalence of Glaucoma in the United States
5.5.2. Type-specific Diagnosed Prevalence of Glaucoma in the United States
5.5.3. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma (OAG) in the United States
5.5.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States
5.5.5. Gender-specific Diagnosed Prevalence of Glaucoma in the United States
5.5.6. Age-specific Diagnosed Prevalence of Glaucoma in the United States
5.6. EU5
5.6.1. Total Diagnosed Prevalence of Glaucoma in the EU-5
5.6.2. Type-specific Diagnosed Prevalence of Glaucoma in EU-5
5.6.3. Type-specific Diagnosed Prevalence of Open angle Glaucoma in EU-5
5.6.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5
5.6.5. Gender-specific Diagnosed Prevalence of Glaucoma in EU-5
5.6.6. Age-specific Diagnosed Prevalence of Glaucoma in EU-5
5.7. Japan
5.7.1. Total Diagnosed Prevalence of Glaucoma in Japan
5.7.2. Type-specific Diagnosed Prevalence of Glaucoma in Japan
5.7.3. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
5.7.4. Type-Specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in Japan
5.7.5. Gender-specific Diagnosed Prevalence of Glaucoma in Japan
5.7.6. Age-specific Diagnosed Prevalence of Glaucoma in Japan
6. Patient Journey
7. KOL views
8. Appendix
8.1. Report Methodology
8.2. Bibliography
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

Table 1: Summary of Glaucoma Epidemiology, and Key Events (20192032)
Table 2: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
Table 3: Genes associated with the risk of POAG
Table 4 : Genes identified in linkage or association with PACG
Table 5: Clinical findings that define patients seen with Angle-Closure disease
Table 6: Differential Diagnosis for Glaucoma
Table 7: The definitions and levels of evidence to rate individual studies
Table 8: Total Diagnosed Prevalence of Glaucoma in the 7MM, in 00 (20192032)
Table 9: Total Diagnosed Prevalence of Glaucoma in the United State, in 00 (20192032)
Table 10: Type-specific Diagnosed Prevalence of Glaucoma in the US, in 00 (20192032)
Table 11: Type-specific Diagnosed Prevalence of OAG in the United States, in 00 (20192032)
Table 12: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States, in 00 (20192032)
Table 13: Gender-specific Diagnosed Prevalence of Glaucoma in the US, in 00 (20192032)
Table 14: Age-Specific Diagnosed Prevalence of Glaucoma in the United States, in 00 (20192032)
Table 15: Total Diagnosed Prevalence of Glaucoma in EU-5, in 00 (20192032)
Table 16: Type-specific Diagnosed Prevalence of Glaucoma in EU-5, in 00 (20192032)
Table 17: Type-specific Diagnosed Prevalence of OAG in EU-5, in 00 (20192032)
Table 18: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5, in 00 (20192032)
Table 19: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5, in 00 (20192032)
Table 20: Age-Specific Diagnosed Prevalence of Glaucoma in EU-5, in 00 (20192032)
Table 21: Total Diagnosed Prevalence of Glaucoma in Japan, in 00 (20192032)
Table 22: Type-specific Diagnosed Prevalence of Glaucoma, in Japan in 00 (20192032)
Table 23: Type-specific Diagnosed Prevalence of OAG in Japan, in 00 (20192032)
Table 24: Type-specific Diagnosed Prevalence of Secondary OAG in Japan, in 00 (20192032)
Table 25: Gender-specific Diagnosed Prevalence of Glaucoma in Japan, in 00 (20192032)
Table 36: Age-Specific Diagnosed Prevalence of Glaucoma in Japan, in 00 (20192032)

Figure 1: Classification of Glaucoma
Figure 2: Classification of Open-Angle Glaucoma
Figure 3: Risk Factors Associated with POAG
Figure 4: Glaucoma classification and subtypes.
Figure 5: Symptoms of Open-Angle Glaucoma
Figure 6: Symptoms of Closed-angle Glaucoma
Figure 7 : Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by an MYOC mutation
Figure 8: Diagnosis of Glaucoma
Figure 9: Total Diagnosed Prevalence of Glaucoma in the 7MM (20192032)
Figure 10: Total Diagnosed Prevalence of Glaucoma in the United States (20192032)
Figure 11: Type-specific Diagnosed Prevalence of Glaucoma in the US (20192032)
Figure 12: Type-specific Diagnosed Prevalence of OAG in the United States (20192032)
Figure 13: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States (20192032)
Figure 14: Gender-specific Diagnosed Prevalence of Glaucoma in the US (20192032)
Figure 15 Age-Specific Diagnosed Prevalence of Glaucoma in the United States (20192032)
Figure 16: Total Diagnosed Prevalence of Glaucoma in the EU-5 (20192032)
Figure 17: Type-specific Diagnosed Prevalence of Glaucoma in EU-5 (20192032)
Figure 18: Type-specific Diagnosed Prevalence of OAG in EU-5 (20192032)
Figure 19: Type-specific Diagnosed Prevalence of secondary Open-Angle Glaucoma in EU-5 (20192032)
Figure 20: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5 (20192032)
Figure 21 Age-specific Diagnosed Prevalence of Glaucoma in EU-5 (20192032)
Figure 22: Total Diagnosed Prevalence of Glaucoma in Japan (20192032)
Figure 23: Type-specific Diagnosed Prevalence of Glaucoma in Japan (20192032)
Figure 24: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (20192032)
Figure 25: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (20192032)
Figure 26: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (20192032)
Figure 27: Age-specific Diagnosed Prevalence of Glaucoma in Japan (20192032)

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE